Chemotherapy-induced neuropathy enhances CGRP signaling not through increased peptide production but through upregulated CGRP receptor components (Ramp1) and likely increased calcium-dependent peptide release.
2× Ramp1 upregulationCGRP receptor component doubled while peptide levels stayed unchanged or decreased, revealing a sensitization mechanism
What the researchers found
Chronic oxaliplatin treatment did not increase CGRP expression or neuron proportion but caused 2-fold Ramp1 upregulation, suggesting CGRP signaling enhancement through receptor sensitization and increased calcium-dependent release rather than peptide upregulation.
Why it matters
Understanding that CGRP signaling can be enhanced without increased peptide levels has implications for anti-CGRP therapy—receptor sensitization may be more important than peptide quantity in some pain conditions.
How the study worked
Eight-week chronic oxaliplatin treatment in mice with behavioral testing (cold allodynia), nerve conduction studies, qPCR and protein analysis of DRG, immunofluorescence for CGRP neurons, and RNA-seq for pathway analysis.
What this study cannot tell us
Mouse model may not fully recapitulate human CIPN. Sex-specific differences (CGRP decrease in females) complicate interpretation. Increased release hypothesis needs direct experimental confirmation.
How to read the evidence
Well-designed preclinical study with multi-modal analysis (behavioral, electrophysiological, molecular, transcriptomic). Novel mechanistic insight needing validation.
When this study was published
Published in 2025.
The bigger picture
This revises the understanding of CGRP in neuropathic pain and suggests that targeting CGRP receptor sensitization (rather than blocking peptide) could be a more effective therapeutic strategy for chemo-induced neuropathy.
Questions still open
- Would anti-CGRP receptor antibodies (erenumab) be more effective than anti-CGRP peptide antibodies for CIPN?
- Can TRPA1 channel blockers prevent CGRP-mediated chemo-induced neuropathy?
- Do the sex differences in CGRP response have clinical implications for CIPN treatment?
Common questions
Can migraine drugs help with chemo nerve pain?
Why does the CGRP receptor matter more than the peptide here?
Read the original research
EXPRESS: CGRP Expression and Signaling Sensitization in a Mouse Model of Chronic Oxaliplatin-Induced Peripheral Neuropathy.
Molecular pain, 17448069261432028
Citation
Du, Junwei; Sudlow, Leland C; Satish, Kanishk; Villagomez, Abraham; Hu, Hongzhen; Berezin, Mikhail Y; Johnson, Maggie. (2026). EXPRESS: CGRP Expression and Signaling Sensitization in a Mouse Model of Chronic Oxaliplatin-Induced Peripheral Neuropathy.. Molecular pain, 17448069261432028. https://doi.org/10.1177/17448069261432028